| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/15/2001 | WO2001010439A1 Cyclic amine ccr3 antagonists |
| 02/15/2001 | WO2001010427A2 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | WO2001010425A2 Use of cgrp antagonists and cgrp release inhibitors for controlling menopausal hot flashes |
| 02/15/2001 | WO2001010387A2 Antiviral therapy use of p-glycoprotein modulators |
| 02/15/2001 | WO2001010385A2 1,4-substituted 4,4-diaryl cyclohexanes |
| 02/15/2001 | WO2001010383A2 Caspase inhibitors and uses thereof |
| 02/15/2001 | WO2001010380A2 Benzanilides as potassium channel openers |
| 02/15/2001 | WO2001010365A1 Patient temperature regulation method and apparatus |
| 02/15/2001 | WO2001010344A1 Nitric oxide releasing medical devices |
| 02/15/2001 | WO2001010323A1 Method of controlling body temperature while reducing shivering |
| 02/15/2001 | WO2001010199A1 A knockout mouse for the tumor suppressor gene anx7 |
| 02/15/2001 | WO2000069900A3 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/15/2001 | WO2000069884A3 Compositions isolated from skin cells and methods for their use |
| 02/15/2001 | WO2000068385A3 Novel nucleic acids and proteins with growth hormone activity |
| 02/15/2001 | WO2000066709A3 Zymogen activation system |
| 02/15/2001 | WO2000066584B1 1-AMINO TRIAZOLO¢4,3-a! QUINAZOLINE-5-ONES AND OR -5-THIONES INHIBITING PHOSPHODIESTERASE IV |
| 02/15/2001 | WO2000065054A3 Human membrane-associated proteins |
| 02/15/2001 | WO2000064946A3 Compositions and methods for cancer treatment by selectively inhibiting vegf |
| 02/15/2001 | WO2000064874A3 Heterosubstituted pyridine derivatives as pde 4 inhibitors |
| 02/15/2001 | WO2000061184A3 Dry formulation for transcutaneous immunization |
| 02/15/2001 | WO2000059513A8 NON-CALCEMIC, ANTIPROLIFERATIVE, TRANSCRIPTIONALLY ACTIVE SULFUR-CONTAINING ANALOGS OF 1α, 25-DIHYDROXY VITAMIN D¿3? |
| 02/15/2001 | WO2000059483A3 Transdermal drug delivery devices comprising a polyurethane drug reservoir |
| 02/15/2001 | WO2000057920A3 Method for expressing proteins |
| 02/15/2001 | WO2000056866A3 Akt-3 nucleic acids, polypeptides, and uses thereof |
| 02/15/2001 | WO2000049144A3 Pyk2 binding proteins |
| 02/15/2001 | WO2000044908A3 Comp/tsp-1, comp/tsp-2 and other tsp chimeric proteins |
| 02/15/2001 | WO2000043419A3 Exocytosis pathway proteins and methods of use |
| 02/15/2001 | WO2000039154A8 Peptides of the at1 receptor and their use for preeclampsia and malign hypertension |
| 02/15/2001 | WO2000002573A8 Natural composition and method for the treatment of sexual dysfunction |
| 02/15/2001 | WO1999046366A8 Uses for humane non-autologous mesenchymal stem cells |
| 02/15/2001 | WO1999042102A8 Indole-3-propionic acids, salts and esters thereof used as medicaments |
| 02/15/2001 | DE19936780A1 Neue Antagonisten von Integrinrezeptoren New antagonists of integrin |
| 02/15/2001 | DE19936719A1 Substituierte 1,5-Dihydropyrrol-2-on-Derivate Substituted 1,5-dihydropyrrol-2-one derivatives |
| 02/15/2001 | CA2381290A1 Bryostatins, bryopyrans and polyketides: compositions and methods |
| 02/15/2001 | CA2381284A1 Fhm, a novel member of the tnf ligand supergene family |
| 02/15/2001 | CA2381215A1 P38map kinase inhibitors |
| 02/15/2001 | CA2381033A1 Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain |
| 02/15/2001 | CA2381008A1 Melanocortin-4 receptor binding compounds and methods of use thereof |
| 02/15/2001 | CA2380759A1 Interleukin-5 inhibiting 6-azauracil derivatives |
| 02/15/2001 | CA2380678A1 Treatment of inflammatory or malignant disease using dnazymes |
| 02/15/2001 | CA2380647A1 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 02/15/2001 | CA2379977A1 Novel integrin receptor antagonists |
| 02/15/2001 | CA2379052A1 Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
| 02/15/2001 | CA2378990A1 1,4-substituted 4,4-diaryl cyclohexanes |
| 02/15/2001 | CA2378984A1 Antiviral therapy use of p-glycoprotein modulators |
| 02/15/2001 | CA2378499A1 Cyclic amine ccr3 antagonists |
| 02/15/2001 | CA2378481A1 A method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate |
| 02/15/2001 | CA2378480A1 Pharmaceutical compositions containing tripeptides |
| 02/15/2001 | CA2378445A1 Use of anti-muscarinic agents for treating skin disorders |
| 02/15/2001 | CA2378310A1 Arylsulfonamido-substituted hydroxamic acid derivatives |
| 02/15/2001 | CA2378292A1 A knockout mouse for the tumor suppressor gene anx7 |
| 02/15/2001 | CA2378241A1 Benzanilides as potassium channel openers |
| 02/15/2001 | CA2378032A1 Crystallization and structure determination of staphylococcus aureus udp-n-acetylenolpyruvylglucosamine reductase (s. aureus murb) |
| 02/15/2001 | CA2376065A1 Crystallization and structure determination of staphylococcus aureus elongation factor p |
| 02/15/2001 | CA2374745A1 Proteases and protease inhibitors |
| 02/14/2001 | EP1075535A1 A method for diagnosing and treating chronic pelvic pain syndrome |
| 02/14/2001 | EP1075530A1 Genomic sequences upstream of the coding region of the g-csf gene for protein production and delivery |
| 02/14/2001 | EP1075529A1 Molecular regulatory circuits to achieve sustained activation of genes of interest by a single stress |
| 02/14/2001 | EP1075528A1 Endothelin-converting-enzyme like protein |
| 02/14/2001 | EP1075519A2 Inhibitors of nf-kb activation |
| 02/14/2001 | EP1075518A2 Human transcriptional regulator molecules |
| 02/14/2001 | EP1075494A2 Compounds and methods for modulating nonclassical cadherin-mediated functions |
| 02/14/2001 | EP1075492A1 Melanocortin 1 receptor selective compounds |
| 02/14/2001 | EP1075491A2 Pth2 receptor selective compounds |
| 02/14/2001 | EP1075490A1 Frameshift mutants of beta-amyloid precursor protein and ubiquitin-b and their use |
| 02/14/2001 | EP1075489A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues |
| 02/14/2001 | EP1075478A1 Phenylurea and phenylthio urea derivatives |
| 02/14/2001 | EP1075476A1 Novel benzimidazoles and benzoxazoles |
| 02/14/2001 | EP1075475A1 Heterocyclic carboxamide derivatives as inhibitors of nitric oxide production |
| 02/14/2001 | EP1075472A1 Prodrugs of benzofuranylmethyl carbamate nk 1? antagonists |
| 02/14/2001 | EP1075471A1 Indolyl derivatives as serotonergic agents |
| 02/14/2001 | EP1075467A1 Pyrazole derivatives as p-38 map kinase inhibitors |
| 02/14/2001 | EP1075282A1 Peg-lhrh analog conjugates |
| 02/14/2001 | EP1075280A2 Hemoglobine-haptoglobin complexes for targeted durg delivery |
| 02/14/2001 | EP1075277A2 Methods for detecting and inhibiting angiogenesis |
| 02/14/2001 | EP1075273A2 Inhibiton of helicobacter pylori proliferation |
| 02/14/2001 | EP1075272A1 Methods for treating diabetes by inhibiting gdf-8 |
| 02/14/2001 | EP1075271A2 Method of treating interstitial cystitis with recombinant heparin-binding epidermal growth factor-like growth factor (hb-egf) |
| 02/14/2001 | EP1075270A1 Short peptides for treatment of neurological degenerative diseases |
| 02/14/2001 | EP1075266A1 Hematopoietic stimulation |
| 02/14/2001 | EP1075264A1 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol |
| 02/14/2001 | EP1075260A2 Novel fatty acid analogues for the treatment of primary and secondary restenosis |
| 02/14/2001 | EP1075259A1 Novel fatty analogues for the treatment of diabetes |
| 02/14/2001 | EP1075258A1 Novel fatty analogues for the treatment of obesity, hypertension and fatty liver |
| 02/14/2001 | EP1075256A1 Arylhydrocarbon receptor ligand antagonists |
| 02/14/2001 | EP1075255A1 Inhibition of binding of hox and homeodomain-containing proteins and uses thereof |
| 02/14/2001 | EP1075184A1 Compositions and methods for active vaccination |
| 02/14/2001 | EP0983380A4 Methods for treating bipolar mood disorder associated with markers on chromosome 18q |
| 02/14/2001 | EP0968226A4 G-rich oligo aptamers and methods of modulating an immune response |
| 02/14/2001 | EP0815120B1 17-difluoromethylene-oestratrienes |
| 02/14/2001 | EP0738280B1 Superactive vip antagonists |
| 02/14/2001 | EP0643071B1 Compound for inhibiting bone resorption and accelerating osteogenesis |
| 02/14/2001 | CN1284134A Methods of producing anti-angiogenic proteins: endostation, angiostation or restin, using pichia yeast expression system |
| 02/14/2001 | CN1284130A Mutants of endostation, 'EM1' having ant-angiogenic activety and methods of use thereof |
| 02/14/2001 | CN1284077A Purine derivatives having phosphodiesterase IV inhibition activity |
| 02/14/2001 | CN1284074A Novel compounds |
| 02/14/2001 | CN1284073A 5-(2-imidazolinylamino)-benzimidazole derivatives, their prepn. and their use as alpha-adrenoceptor agonists with inproved metabolic stability |
| 02/14/2001 | CN1284072A Prodrugs of aspartyl protease inhibitors |
| 02/14/2001 | CN1284071A Sulphona mide derivatives as prodrugs of aspartyl protease inhibitors |
| 02/14/2001 | CN1284066A Substituted inidazole derivatives having agonist-like activity at alpha 2B or 2B/2C adrenergic receptors |